Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose
In the next five years, an additional 75,000 seats are expected to be added across both undergraduate and postgraduate levels
The event will be attended by 35,000+ industry professionals
Agreement adds a new preclinical ADC with potential for enhanced anti-tumour activity and best-in-class profile
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
Telangana aims to increase the value of the Life Sciences economy from US$ 80 billion to US$ 250 billion by 2030
Revenues up 13.1% year-over-year; Continued momentum driven by organic growth, strategic partnerships, and acquisitions
Efdoralprin Alfa was well tolerated, with a safety profile comparable to plasma-derived therapy
Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services
INEOS production of BDO in Germany, which produces a vital ingredient for antibiotics, statins and vitamin B6, is being crushed by a flood of carbon heavy imports and product dumping from the Far East
Subscribe To Our Newsletter & Stay Updated
